高钾血症相关住院后的出院后医疗费用与再入院负担
基于IBM MarketScan数据库(2010-2014年),将高钾血症住院成人患者与无高钾血症住院患者按年龄、CKD分期、心衰、透析、RAAS抑制剂使用及主要诊断类别1:1匹配。高钾血症相关住院患者出院后1年总医疗费用更高($68,861 vs. $38,482),再入院率、住院时长及医疗资源使用均显著增加。
要点
- 高钾血症相关住院患者出院后1年总费用比对照高$30,379(95%CI $25,423-$35,335)。
- 高钾血症相关住院再入院率更高:30天0.15 vs. 0.09,60天0.25 vs. 0.16,90天0.36 vs. 0.23。
- 高钾血症相关住院再入院总住院日更长(10.5 vs. 5.8天),每次再入院住院日也更长(8.1 vs. 7.1天)。
核心结论
- 高钾血症相关住院与出院后1年显著的经济负担和再入院负担相关。
研究设计与样本
- 高钾血症住院成人患者按年龄、CKD分期、心衰、透析、RAAS抑制剂使用及主要诊断类别与无高钾血症住院患者1:1匹配。
- 高钾血症住院患者n=4,426用于费用和资源利用分析;高钾血症相关住院n=5,377用于再入院和住院时长分析。
主要发现
- 高钾血症住院患者出院后1年总全因费用为$68,861,对照为$38,482,差异$30,379(95%CI $25,423-$35,335)。
- 高钾血症住院患者出院后1年住院次数(1.0 vs. 0.4)、急诊就诊(2.0 vs. 1.2)和门诊就诊(49.6 vs. 39.1)均更高(所有P<0.001)。
- 高钾血症相关住院再入院率在30天(0.15 vs. 0.09)、60天(0.25 vs. 0.16)、90天(0.36 vs. 0.23)均更高(所有P<0.001)。
- 高钾血症相关住院每次再入院住院日更长(8.1 vs. 7.1天),总住院日更长(10.5 vs. 5.8天)(所有P<0.001)。
- 在各合并症亚组中观察到相似趋势。
临床怎么用
- 肾内科智能体应关注高钾血症住院患者出院后的再入院风险和经济负担,加强出院后随访与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Limited evidence is available regarding the postdischarge economic and readmission burdens of hyperkalemia. METHODS: Using the IBM MarketScan Commercial and Medicare-Supplemental Claims database (January 1, 2010-December 31, 2014), adult patients with a hospitalization with a hyperkalemia diagnosis (ICD-9-CM 276.7, hyperkalemia cohort) were 1:1 matched with patients with a hospitalization without evidence of hyperkalemia (nonhyperkalemia cohort) on age, chronic kidney disease stage, heart failure, dialysis, renin-angiotensin-aldosterone system inhibitor use, and major diagnostic categories of the hospitalization. All-cause health care costs and health care resource utilization measures were compared between cohorts during the 1-year postdischarge period. Postdischarge readmission and length of stay (LOS) were compared between hyperkalemia-related hospitalizations from the hyperkalemia cohort and matched hospitalizations unrelated to hyperkalemia from the nonhyperkalemia cohort. RESULTS: Patients with hyperkalemia-related hospitalizations (n = 4426) incurred $30,379 (95% confidence interval, $25,423-$35,335) higher 1-year total all-cause costs ($68,861 vs. $38,482) and had higher rates of inpatient admissions (1.0 vs. 0.4), emergency department visits (2.0 vs. 1.2), and outpatient visits (49.6 vs. 39.1) than the nonhyperkalemia cohort during the 1-year postdischarge study period (all P < 0.001). Hyperkalemia-related hospitalizations (n = 5377) were associated with significantly higher readmission rates (within 30 days: 0.15 vs. 0.09; 60 days: 0.25 vs. 0.16; 90 days: 0.36 vs. 0.23; all P < 0.001), longer LOS per readmission (8.1 vs. 7.1 days), and longer total inpatient days (10.5 vs. 5.8 days) compared with hospitalizations unrelated to hyperkalemia (all P < 0.001). Similar trends were observed across comorbidity subgroups. CONCLUSION: Hyperkalemia-related hospitalizations were associated with significant economic and readmission burdens during the 1-year postdischarge period.
引用
- Betts KA, Woolley JM, Mu F, et al. Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations. Kidney Int Rep. 2020. PMID: 32775827. doi:10.1016/j.ekir.2020.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。